Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Sidoti Micro Cap Conference 2023
29 slides from Nemaura Medical's conference presentation, Nov 14, 2023
Slide 1: Corporate Presentation, Sidoti Micro Cap Conference
Corporate Presentation Sidoti Micro Cap Conference Dr Faz Chowdhury, CEO 15 th November 2023 Nasdaq: NMRD
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms su
Slide 3: Clinical Need
Clinical Need… Obesity and Diabetes are two of the major drivers of the chronic disease epidemic . 96 Million people had pre - diabetes in the USA alone, in 2019 1 Over 40 % of the US Adult population suffers from obesity 2
Slide 4: Clinical Need
Clinical Need… The tide of chronic disease conditions cannot be turned unless these two drivers, obesity and pre - diabetes are addressed .
Slide 5: Non-invasive daily wear continuous glucose sensor
To address this, we developed a Non - invasive daily wear continuous Glucose sensor targeting: Clinical Market: Type 2 diabetes: >60 million people in Europe 2 Consumer market: Pre - diabetes and Obesity: >90 million people 1 in USA [This market is currently deemed to be the largest opportunity for
Slide 6: Key Achievements
Key Achievements 1. Developed a world - first wearable device with a daily disposable glucose sensor. 2. CE Approved Class 2b Medical device in Europe 3. Approved by the Saudi Arabia Food and Drug Agency 4. Launched sensor sales via consumer program in UK, with other territories to follow
Slide 7: sugarBEAT Example of Volunteer data
sugarBEAT ® Example of Volunteer data compared with BGM and Invasive CGM Blue: Finger Prick BGM (Blood glucose meter) Red: Invasive CGM sugarBEAT® Raw data presented (prior to algorithmic conversion, demonstrating tight correlation)
Slide 8: sugarBEAT Example of Volunteer data (Non-diabetic)
sugarBEAT ® Example of Volunteer data (Non - diabetic)
Slide 9: Our Solution: A digital biomarker
Our Solution: A digital biomarker, as part of a consumer metabolic health program The Meta - Score is a digital biomarker, and a number between 10 and 100 that is derived from human behavioral patterns and a body worn sensor that measures insulin resistance or sensitivity .
Slide 10: Our Solution: A digital biomarker
Our Solution: A digital biomarker, as part of a consumer metabolic health program Clinical evidence demonstrates that poor glucose control can be a cause of Dementia, Diabetes, Cardiovascular complications and obesity 3 .
Slide 11: Our Solution: Miboko digital program
Our Solution: A digital biomarker The digital program has been branded Miboko : Mind, Body, Konnect . The sensor is one of a kind, non - invasive single day use . As little as one sensor is needed per month .
Slide 12: Augmented with GLP-Agonists
Augmented with GLP - 1 Agonists GLP – 1 Agonists, not only improve blood sugar control but has shown significant weight loss . Studies have shown that people using Semaglutide and making lifestyle changes lost about 34 pounds (over 15 Kg) versus less than 6 pounds (or 2 . 6 Kg) for those who did not
Slide 13: Miboko: Mind + Body + Konnect
XIUBOKO MIND + BODY + KONNECT
Slide 14: A Mass-Market Consumer Product
Miboko : A Mass - Market Consumer Product Download the app and On - board Sensor measures metabolic health score Receive report and weekly targets
Slide 15: A Mass-Market Consumer Product
Miboko : A Mass - Market Consumer Product Download the app and On - board Achievable lifestyle targets are set automatically after on - boarding
Slide 16: A Mass-Market Consumer Product
Miboko : A Mass - Market Consumer Product Download the app and On - board Achievable lifestyle targets are set automatically after on - boarding
Slide 17: A Mass-Market Consumer Product
Miboko : A Mass - Market Consumer Product Body worn sensor measures the Meta - score, based on insulin resistance, once or twice a month, and eventually potentially only once every 2 - 3 months.
Slide 18: A Mass-Market Consumer Product
Miboko : A Mass - Market Consumer Product The Meta - score is a digital biomarker that combines insulin sensitivity with behavioral patterns. It provides a single number/score providing a holistic representation of a persons state of metabolic health
Slide 19: Results
Miboko : Results One of a kind body worn sensor Insight into metabolic health through an AI driven digital biomarker Easy to use, minimum user burden Low cost Intended as a companion for life, and the meta - score will become synonymous with sustained good metabolic health
Slide 20: Market - USA
Miboko : Market - USA Over 100 million potential customers 1,2 Anticipate reimbursement by healthcare providers and employers Gross margins expected to be > 70% (or over 50% with drugs)
Slide 21: Market - KSA
Miboko : Market - KSA According to the World Health Organization (WHO), Saudi Arabia has the second - highest rate of diabetes in the Middle East and the seventh - highest globally 7 . Around 7 million Saudis (24%) are diabetic, while almost 3 million have prediabetes 8 . It is estimated that diabet
Slide 22: Key Competition
Miboko : Key Competition Noom: Over 50 million Subscribers, (of which approximately 2 million are paid subscribers), >$400m Revenues in 2020 4 Miboko USP: A holistic Metabolic health approach to sustained good metabolic health through sustainable weight loss and insight into insulin sensitivity – wi
Slide 23: Key Competition
Miboko : Key Competition What about other competition with programs using Invasive 10 - 14 day CGM? Invasive CGM’s require a prescription in the U.S. Skin trauma from Needle and/or adhesive Reports of pain when pulling sensor filament out of arm These factors make invasive sensors challenging for a
Slide 24: Key Competition
Miboko : Key Competition Bruising on Skin will make consumer uptake challenging: Example of bruising on skin from application of 6 invasive sensors over a 3 - 4 month period Whilst this is acceptable in the medical space, it poses significant challenges in the consumer space.
Slide 25: Growth Plans
Growth Plans ▪ Partner with companies with existing sales infrastructure for B to C route ▪ Sell to employers and insurers to complement their existing offerings
Slide 26: Key Highlights
Key Highlights ▪ One of the fastest growing areas of healthcare – weight loss, and preventative health management through the use of low - cost body worn sensor and digital biomarker ▪ First mover advantage with daily wear non - invasive sensor ▪ Commenced Commercialisation in UK, and to be followed
Slide 27: Future Targets
Future Targets ▪ Launch sugarBEAT ® as a standlone medical device CGM sensor in UK and KSA ▪ Complete development of Lactate sensor and partner/license sensor for sports/personal training market ▪ Partner Miboko in global territories with focus on USA ▪ Achieve FDA PMA approval for 24 - hour sugarBE
Slide 28: References
References 1. https://www.cdc.gov/diabetes/data/statistics - report/prevalence - of - prediabetes.html#:~:text=An%20estimated%2096%20million%20adults,A1C%20level%20(Table%2 03) . 2. https://www.niddk.nih.gov/health - information/health - statistics/overweight - obesity 3. https://www.health.harvard.
Slide 29: References
References 8. Naeem Z: Burden of diabetes mellitus in Saudi Arabia . Int J Health Sci (Qassim). 2015, 9:5 - 7. 10.12816/0024690 9. Al Dawish MA, Robert AA, Braham R, Al Hayek AA, Al Saeed A, Ahmed RA, Al Sabaan FS: Diabetes mellitus in Saudi Arabia: a review of the recent literature. Curr Diabetes R